生物标志物检测在非小细胞肺癌靶向突变中的诊断和经济价值：文献综述。
Diagnostic and economic value of biomarker testing for targetable mutations in non-small-cell lung cancer: a literature review.
机构信息
US Health Economics and Outcomes Research, EMD Serono, Inc., An affiliate of Merck KGaA, Rockland, MA 02370, USA.
Global Evidence & Value Development, Merck Healthcare KGaA, Darmstadt, Germany.
出版信息
Future Oncol. 2022 Feb;18(4):505-518. doi: 10.2217/fon-2021-1040. Epub 2021 Dec 6.
We aimed to assess the diagnostic and economic value of next-generation sequencing (NGS) versus single-gene testing, and of liquid biopsy (LBx) versus tissue biopsy (TBx) in non-small-cell lung cancer biomarker testing through literature review. Embase and MEDLINE were searched to identify relevant studies (n = 43) from 2015 to 2020 in adults with advanced non-small-cell lung cancer. For NGS versus single-gene testing, concordance was 70-99% and sensitivity was 86-100%. For LBx versus TBx, specificity was 43-100% and sensitivity was ≥60%. Turnaround times were longer for NGS versus single-gene testing (but not vs sequential testing) and faster for LBx versus TBx. NGS was cost-effective, and LBx reduced US per-patient costs. NGS versus single-gene testing and LBx versus TBx were concordant. NGS and LBx may be cost-effective for initial screening.
我们旨在通过文献回顾评估下一代测序（NGS）与单基因检测相比，以及液体活检（LBx）与组织活检（TBx）在非小细胞肺癌生物标志物检测中的诊断和经济价值。检索了 Embase 和 MEDLINE，以确定 2015 年至 2020 年期间成人晚期非小细胞肺癌相关的 43 项研究。对于 NGS 与单基因检测相比，一致性为 70-99%，敏感性为 86-100%。对于 LBx 与 TBx 相比，特异性为 43-100%，敏感性≥60%。与单基因检测相比，NGS 的检测周转时间更长（但与顺序检测相比没有），而 LBx 比 TBx 更快。NGS 具有成本效益，而 LBx 降低了每位患者的美国医疗费用。NGS 与单基因检测以及 LBx 与 TBx 是一致的。NGS 和 LBx 可能对初始筛查具有成本效益。
Zotero 插件